CN105209056B - Tafa4化合物及其用于治疗疼痛的用途 - Google Patents

Tafa4化合物及其用于治疗疼痛的用途 Download PDF

Info

Publication number
CN105209056B
CN105209056B CN201480025716.5A CN201480025716A CN105209056B CN 105209056 B CN105209056 B CN 105209056B CN 201480025716 A CN201480025716 A CN 201480025716A CN 105209056 B CN105209056 B CN 105209056B
Authority
CN
China
Prior art keywords
pain
tafa4
neurons
protein
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480025716.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105209056A (zh
Inventor
A.莫克里克
M-C.德尔菲尼
A.曼蒂勒里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Aix Marseille Universite
Original Assignee
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Universite de la Mediterranee Aix Marseille II
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL CENTER FOR SCIENTIFIC RESEARCH, Universite de la Mediterranee Aix Marseille II filed Critical NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Publication of CN105209056A publication Critical patent/CN105209056A/zh
Application granted granted Critical
Publication of CN105209056B publication Critical patent/CN105209056B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201480025716.5A 2013-05-06 2014-05-06 Tafa4化合物及其用于治疗疼痛的用途 Active CN105209056B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305592.1 2013-05-06
EP13305592.1A EP2801369A1 (en) 2013-05-06 2013-05-06 TAFA4 compounds and uses thereof for treating pain
PCT/EP2014/059247 WO2014180853A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Publications (2)

Publication Number Publication Date
CN105209056A CN105209056A (zh) 2015-12-30
CN105209056B true CN105209056B (zh) 2018-01-23

Family

ID=48428409

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480025716.5A Active CN105209056B (zh) 2013-05-06 2014-05-06 Tafa4化合物及其用于治疗疼痛的用途

Country Status (8)

Country Link
US (2) US9884088B2 (https=)
EP (2) EP2801369A1 (https=)
JP (1) JP6487419B2 (https=)
CN (1) CN105209056B (https=)
CA (2) CA2910652C (https=)
DK (1) DK2994157T3 (https=)
ES (1) ES2813629T3 (https=)
WO (1) WO2014180853A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107430121B (zh) * 2015-03-13 2020-06-23 希森美康株式会社 受试物质的检测方法及在该方法中使用的试剂盒
EP3703558A4 (en) * 2017-10-30 2021-08-11 The Regents of The University of California CALIBRATION-FREE IN-VIVO MEASUREMENT OF ANALYTES USING ELECTROCHEMICAL SENSORS
CA3097999A1 (en) 2018-04-24 2019-10-31 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
EP3856228B1 (en) * 2018-09-27 2023-03-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Tafa4 polypeptide for use for reducing skin inflammation
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
JP2023511762A (ja) * 2020-02-04 2023-03-22 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 炎症性疾患の処置のための方法及び医薬組成物
CA3167629A1 (en) * 2020-02-13 2021-08-19 Alexander Theodore CHESLER Margaric acid decreases piez02-mediated pain
CA3239578A1 (en) 2021-12-17 2023-06-22 Stephane GAILLARD Peptides and methods for use in treating pain
WO2023122436A2 (en) * 2021-12-20 2023-06-29 Amgen Inc. Dll3 binding peptides and uses thereof
EP4499163A1 (en) * 2022-03-24 2025-02-05 Baxter International Inc. Dialysis system having thermoelectric heating
AR129441A1 (es) 2022-05-25 2024-08-28 Tafalgie Therapeutics Péptidos y métodos para el tratamiento del dolor
JP2025520099A (ja) * 2022-05-31 2025-07-01 ニューラクル ジェネティクス インコーポレイテッド 網膜又は黄斑疾患治療用組成物
JP2026509101A (ja) 2023-02-17 2026-03-17 ナオス・インスティテュート・オブ・ライフ・サイエンス 皮膚耐性閾値を増加させることが可能な生態生物学的化合物の選択のための方法
WO2025116606A1 (ko) * 2023-11-30 2025-06-05 주식회사 뉴라클제네틱스 신규한 케모카인-유사 단백질 단편
CN121249875B (zh) * 2025-10-13 2026-03-20 上海交通大学医学院附属仁济医院 外周神经系统中的Mas相关G蛋白耦联受体D在缓解阿片类药物耐受中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090077680A1 (en) * 2000-06-12 2009-03-19 Alejandro Abuin Genetically Engineered and Photyped Mice and Stem Cell Clones for Producing the Same
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32

Also Published As

Publication number Publication date
EP2994157B1 (en) 2020-07-01
CA2910652A1 (en) 2014-11-13
US20180110829A1 (en) 2018-04-26
US9884088B2 (en) 2018-02-06
DK2994157T3 (da) 2020-08-24
ES2813629T3 (es) 2021-03-24
US20160113996A1 (en) 2016-04-28
CA2910652C (en) 2024-05-28
EP2801369A1 (en) 2014-11-12
EP2994157A1 (en) 2016-03-16
JP6487419B2 (ja) 2019-03-20
WO2014180853A1 (en) 2014-11-13
CA3235916A1 (en) 2014-11-13
CN105209056A (zh) 2015-12-30
JP2016519138A (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
CN105209056B (zh) Tafa4化合物及其用于治疗疼痛的用途
JP2010509235A (ja) 多発性硬化症の治療
US9125862B2 (en) Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor
Ko et al. Spinal activity of interleukin 6 mediates myelin basic protein-induced allodynia
Yin et al. RGS5 augments astrocyte activation and facilitates neuroinflammation via TNF signaling
AU2018217328A1 (en) Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
KR20200136939A (ko) 천식 또는 알레르기성 질환을 치료하는 방법
US20110237515A1 (en) Peptide derived from neurotesin receptor 3 and use thereof in the treatment of psychiatric diseases
Tu et al. Leukemia inhibitory factor (LIF) potentiates antinociception activity and inhibits tolerance induction of opioids
Class et al. Patent application title: TAFA4 COMPOUNDS AND USES THEREOF FOR TREATING PAIN Inventors: Aziz Moqrich (Marseille, FR) Marie-Claire Delfini (Marseille, FR) Annabelle Mantilleri (Apt, FR)
US20110189194A1 (en) Use of cd95 inhibitors for the treatment of inflammatory disorders
CN102648977B (zh) 滤泡素抑制素样蛋白1在调节钠钾atp酶活性中的用途
Kamalova Functional characterization of an AMPA receptor auxiliary subunit GSG1L in vivo
Fuller An investigation into noxious mechanosensation, and the role of peripheral neuron subpopulations in pain
Rees Characterization of the 15q13. 3 Microdeletion and Its Effects on Neuronal Excitability, Astrocyte α7 Nicotinic Acetylcholine Receptor Dynamics, and Neuroinflammation
Li Neuronal Interleukin-13 (IL-13) Modulates Synaptic Physiology and Neuronal Resilience to Trauma
Mousseau Microglial Panx1 is a Spinal Determinant of Arthritis Joint Pain
De Rocco Pharmacological modulation of neuronal activity for the treatment of Rett syndrome
Lin Cell Type-Specific FGF13 Regulation of Neuronal Function
Marini The role of schwann cell TRPA1 in cancer pain and perineural nerve invasion
Sironi Loss of C9orf72 Function Impairs the Peripheral Neuromuscular System and Anticipates Symptoms in ALS Mice
CN116234908A (zh) 促进foxp3s的吗啉代物
HK40100341A (zh) 靶向pacs1的化合物及其使用方法
Althoff et al. 54. Annual Meeting of the German Society of Neuropathology and Neuroanatomy (DGNN)“Neuropathology in the 21st Century”
O'donnell Glutamate transport affects mitochondria and calcium signaling in astrocytic processes under normal and pathological conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant